1. Quinlivan EP, McPartin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002;359:227-8.
2. Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease. JAMA 2001;286:936-43.
3. Trushina, E. and C. T. McMurray (2007). "Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases." Neuroscience 145(4): 1233-48.
4. High levels of oxidative stress in people with coronary heart disease, previously thought to be a marker of the heart condition, could instead indicate a condition of glucose abnormality, such as overt type 2 diabetes. Dr Saverio Stranges, Associate Professor of Cardiovascular Epidemiology at Warwick Medical School - 2008.
METHYVORIN is not a drug and is not intended to diagnose, treat, cure or prevent heart disease, heart attack, stroke, cardiovascular conditions, cancer or any other disease. METHYVORIN should not be considered equivalent to or a substitute for an FDA-approved drug. METHYVORIN and its logo are trademarks of KH Corp.
Placing an order indicates that you understand and agree to the Terms and Conditions of Sale.
The statements on the methyvorin.com website have not been evaluated by the Food and Drug Administration. METHYVORIN is a dietary supplement, not a drug. METHYVORIN is not intended to diagnose, treat, cure or prevent any disease.
Statements that ingredients found in METHYVORIN have been proven in clinical trials to effectively treat a disease do not represent any claim regarding the effects of METHYVORIN and do not signify that METHYVORIN itself has been proven to effectively treat that disease.